Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Participants needed: 240
Trial details
Phase: Phase 2Age: 60+Biological sex: AllType: InterventionalSponsor: Apellis Pharmaceuticals, Inc.Updated: Jun 24, 2026Locations: 78
Eligibility criteria

The study eye must meet all inclusion criteria. If both eyes meet the inclusion... [+16]

Uncontrolled, clinically relevant history of any gastrointestinal, renal, hepati... [+25]

Read more
Status: Recruiting

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).

Participants needed: 12
Trial details
Phase: Phase 2Age: 12-17Biological sex: AllType: InterventionalSponsor: Apellis Pharmaceuticals, Inc.Updated: Jun 26, 2026Locations: 12
Eligibility criteria

Are 12-17 years old at the time of screening [+5]

Are an adult, 18 years of age or older, with PNH [+3]

Read more